Abvc Biopharma, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
ABVC Biopharma's Chairman and Chief Business Officer, Eugene Jiang, has significantly increased his voting control over the company's common stock, now holding 18.50% of outstanding shares through direct ownership and various voting agreements.
NASDAQ
SCHEDULE 13D: ABVC BioPharma Chairman Eugene Jiang Consolidates Significant Voting Control, Boosting Stake to 17.4%
ABVC BioPharma, Inc. Chairman and Chief Business Officer Eugene Jiang has significantly increased his voting control over the company's common stock to 17.4% through direct holdings and new voting proxy agreements with investors.